血透联合左卡尼汀法在终末期糖尿病肾病患者治疗中的应用价值

In the End of Hemodialysis Combined with Levocarnitine Application Value in the Treatment of Patients with End-stage Diabetic Nephropathy

目的讨论血透联合左卡尼汀法在终末期糖尿病肾病患者治疗中的应用价值。方法选取2013年4月—2015年3月间于该院住院治疗的终末期糖尿病肾病患者共90例,将其以随机分组的形式平均分为对照组以及实验组,对照组行常规血液透析,实验组于常规组基础上与左卡尼汀联合治疗,对比两组患者胆固醇、血红/白蛋白、血肌酐含量,同时观察两组不良反应的产生。结果对照组与实验组相比较,血红/白蛋白水平明显较低,经统计学分析,差异有统计学意义(P<0.05),血肌酐与胆固醇水平明显较高,经统计学分析,差异有统计学意义(P<0.05),于不良反应情况上明显较高,且差异有统计学意义(P<0.05)。结论使用常规治疗联合左卡尼汀法对终末期糖尿病肾病患者进行治疗,可减少患者营养不良、贫血等情况的产生,且并发症较少,具有显著临床意义。

Objective To discuss the method of hemodialysis combined with Levocarnitine in the final application value in the treatment of patients with end-stage diabetic nephropathy. Methods A total of 2013 April to 2015 3 months in our hos-pital inpatient treatment of end-stage diabetic nephropathy patients, a total of 90 patients with, the in form of a random packet average as control group and the experimental group, control group underwent conventional hemodialysis, experimen-tal group in the conventional group on the basis of combination therapy with L-carnitine, compared two groups of patients with cholesterol, blood red/ albumin, creatinine （CR）, and observe the adverse reactions of the two groups. Results Control group and experimental group, blood red/ albumin levels were significantly lower, and the statistical analysis, the difference has statistical significance （P〈0.05）, serum creatinine and cholesterol levels were significantly higher, the statistical analy-sis, the difference is statistically significant（P 〈 0.05）, adverse reactions were significantly higher, and the difference has statistical significance （P〈0.05）. Conclusion Using conventional treatment combined with Levocarnitine method for end-stage diabetic nephropathy patients were treated, reduce patients with malnutrition, anemia and less complications, with a significant clinical significance.